19:42:53 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-20 Bokslutskommuniké 2024
2024-11-19 Kvartalsrapport 2024-Q3
2024-08-20 Kvartalsrapport 2024-Q2
2024-05-08 Ordinarie utdelning INDEX 0.00 SEK
2024-05-07 Årsstämma 2024
2024-05-07 Kvartalsrapport 2024-Q1
2024-02-21 Bokslutskommuniké 2023
2023-11-28 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-24 Kvartalsrapport 2023-Q1
2023-05-24 Årsstämma 2023
2023-05-08 Ordinarie utdelning INDEX 0.00 SEK
2023-02-23 Bokslutskommuniké 2022
2022-11-23 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-06-02 Ordinarie utdelning INDEX 0.00 SEK
2022-06-01 Årsstämma 2022
2022-05-16 Kvartalsrapport 2022-Q1
2022-02-23 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-04 Ordinarie utdelning INDEX 0.00 SEK
2021-06-03 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2021-01-12 Extra Bolagsstämma 2020
2020-11-25 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-05-07 Kvartalsrapport 2020-Q1
2020-04-21 Ordinarie utdelning INDEX 0.00 SEK
2020-04-20 Årsstämma 2020
2020-02-20 Bokslutskommuniké 2019
2019-11-27 Kvartalsrapport 2019-Q3
2019-10-09 Extra Bolagsstämma 2019
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-07 Ordinarie utdelning INDEX 0.00 SEK
2019-05-06 Kvartalsrapport 2019-Q1
2019-05-06 Årsstämma 2019
2019-02-20 Bokslutskommuniké 2018
2018-11-19 Kvartalsrapport 2018-Q3
2018-08-28 Kvartalsrapport 2018-Q2
2018-05-25 Ordinarie utdelning INDEX 0.00 SEK
2018-05-24 Årsstämma 2018
2018-05-17 Kvartalsrapport 2018-Q1
2018-02-26 Bokslutskommuniké 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-25 Kvartalsrapport 2017-Q2
2017-05-31 Ordinarie utdelning INDEX 0.00 SEK
2017-05-30 Kvartalsrapport 2017-Q1
2017-05-30 Årsstämma 2017
2017-02-27 Bokslutskommuniké 2016
2016-11-22 Kvartalsrapport 2016-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
InDex Pharmaceuticals är ett läkemedelsutvecklingsbolag med fokus på immunologiska sjukdomar. Bolagets läkemedelskandidat cobitolimod utvärderas i fas III-studien CONCLUDE som en behandling av ulcerös kolit – en funktionsnedsättande, kronisk inflammation av tjocktarmen. Bolaget har också utvecklat en plattform av patentskyddade substanser, så kallade DNA-baserade ImmunModulerande Sekvenser (DIMS), med potential att användas vid behandling av olika immunologiska sjukdomar.
2020-04-08 08:00:00
April 8, 2020 - InDex Pharmaceuticals Holding AB (publ) today announced that the company plans to hold its Annual General Meeting 2020 as scheduled at 5.00 pm on April 20, 2020, but takes precautionary measures.
  • Due to the risk for spread of infection InDex plans to limit the scope of the Annual General Meeting and the presence of the Board of Directors and Management.
  • There will be no presentation by the CEO at the Annual General Meeting. InDex plans to provide update via other channels close to the Annual General Meeting.
  • No food or refreshments will be served.
  • The number of attendees will be limited in accordance with the restrictions in force at the time of the Annual General Meeting.

To ensure the health and safety of our shareholders, employees and other stakeholders, InDex decided on certain precautionary measures related to its Annual General Meeting 2020. InDex is closely monitoring the development around covid-19 and is following recommendations from relevant national authorities, such as The Public Health Agency of Sweden. 

InDex plans to hold its Annual General Meeting 2020 as scheduled at 5:00 pm on April 20, 2020, at Setterwalls Advokabyrå's premises (address Sturegatan 10, Stockholm), but with a limited scope. Due to the risk for infection, InDex has decided to limit the scope of the meeting and the presence of the Board of Directors and Management will be limited.

Individuals who feel sick or where there is a risk of infection are expected to refrain from participating in person. Please refer to the Public Health Agency of Sweden for updated information regarding covid-19, www.folkhalsomyndigheten.se.

Even though InDex is taking precautions to minimize the risk for exposure to covid-19, the company is unable to guarantee that attendees will not be exposed to the virus. InDex would like to remind shareholders of the possibility of not attending the meeting in person. Instead they can appoint a proxy who will vote on their behalf. Shareholders who want to authorize a proxy to vote on their behalf, can find relevant templates at: https://www.indexpharma.com/en/annual-general-meeting-2020/. Please be aware that voting-rights registration may also be required.

 

For more information:
Johan Gileus, CFO
E-mail: johan.gileus@indexpharma.com
 

InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company's lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company's shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm. Redeye AB with e-mail certifiedadviser@redeye.seand phone number +46 8 121 576 90 is the company's Certified Adviser. For more information, please visit www.indexpharma.com

Publication
The information was submitted for publication through the agency of the contact person set out above at 08:00 CET on April 8, 2020.